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Adipose tissue is not considered anymore as a passive depot for storing excess energy in the form of 
triglycerides but as an active organ secreting several hormones or adipokines. This review gives 
some knowledge about history of discovery, ways of measurements, and biochemical and 
pathophysiological effects of adiponectin.  
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diponectin (Synonyms Acrp30, 
GBP28, AdipoQ, apM1 gene product) 
is a novel adipocyte secreting 
hormone discovered in 1995/1996. It is a 
collagen-like plasma protein (247 amino 
acids) specifically synthesized in adipose 
tissue. It account for about 0.05-0.1% of total 
serum proteins.  It is composed of N-terminal 
collagen-like sequence and a C-terminal 
globular region. It circulates in serum as three 
distinct oligomers: trimer, hexamer, and an 
even higher molecular weight species1-6. It 
has several metabolic functions.  
 
History of discovery 
Adiponectin was originally identified 
independently by four groups of scientist 
using different approaches, given different 
names at time of discovery. 
i. Scherer et al. (1995): describe a novel 
30-kDa secretory protein 
nominated as, Acrp30, (adipocyte 
complement-related protein), that 
is exclusively synthesized in 
adipose tissue and secreted into 
serum. Its mRNA is induced over 
100-fold during adipocyte 
differentiation. Acrp30 is a 
relatively abundant serum protein, 
accounting for up to 0.05% of total 
serum protein, contained 247 
amino acids with a predicted 
molecular mass of 28 kDa. Acrp30 
consists of an amino-terminal 
signal sequence, followed by a 
stretch of 27 amino acids that does 
not show significant homology to 
any protein in the Gen-Bank data 
base and then by 22 perfect Gly-X-
Pro or Gly-X-X repeats. The 
carboxyl-terminal globular domain 
exhibits striking homology to a 
number of proteins, such as the 
globular domains of type VIII and 
type X collagens, the subunits of 
complement factor C1q and a 
protein found in the serum of 
hibernating animals during the 
summer months. Structurally, 
albeit not at the primary sequence 
level, the protein resembles the 
lung surfactant protein and the 
hepatocyte mannan-binding 
protein, both of which have 
collagen-like domains and 
globular domains of similar size2. 
ii. Nakano et al. (1996): purified and 
obtained a novel protein, GBP28 
(gelatin-binding protein of 28 
kDa) by the use of affinity to 
gelatin-Cellulofine, from human 
plasma. GBP28 bound to gelatin-
A
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Cellulofine could be eluted with 1 
M NaCl. By analysis of its amino-
terminal amino acid sequences and 
the peptides obtained by protease 
digestion, GBP28 was identified as 
a novel protein, in comparison 
with other proteins in the Gen-
bank data base3,4.  
iii. Maeda et al. (1996): isolated a novel 
adipose-specific gene, apM1, the 
transcript of which is the most 
abundant in the mRNA population 
from human adipose tissue. 
Northern blotting revealed that the 
human apM1 gene transcript is 
exclusively expressed in adipose 
tissue. The apM1 gene encodes a 
244 amino acid open reading 
frame containing a putative signal 
sequence and G-X-Y repeats (66 
amino acids) followed by a cluster 
of aromatic residues near the C 
terminus having high local 
similarity with collagens X and 
VIII and complement factor C1q. 
Thus, apM1 is likely to be a novel 
collagen-like secretory protein 
exclusively produced by adipose 
tissue5.   
The assumed amino acid sequence 
of cDNA clone apM1 contained all 
the sequences of GBP28 and its 
peptides. Therefore, it is evident 
that the cDNA clone apM1 
encodes GBP28 and the protein is 
specific to adipose tissue. 
iv. Hu et al. (1996): Using an mRNA 
differential display technique, they 
isolated a novel adipose cDNA, 
termed adipoQ. The adipoQ cDNA 
encodes a polypeptide of 247 
amino acids with a secretory signal 
sequence at the amino terminus, a 
collagenous region (Gly-X-Y 
repeats), and a globular domain. 
The globular domain of adipoQ 
shares significant homology with 
subunits of complement factor 
C1q, collagen alpha 1(X), and the 
brain-specific factor cerebellin. 
The expression of adipoQ is highly 
specific to adipose tissue in both 
mouse and rat. Expression of 
adipoQ is observed exclusively in 
mature fat cells as the stromal-
vascular fraction of fat tissue does 
not contain adipoQ mRNA. In 
cultured 3T3-F442A and 3T3-L1 
preadipocytes, hormone-induced 
differentiation dramatically 
increases the level of expression 
for adipoQ. Furthermore, the 
expression of adipoQ mRNA is 
significantly reduced in the 
adipose tissues from obese mice 
and humans6. 
 
Measurement of adiponectin 
Blood samples for measurement of fasting 
plasma adiponectin concentrations were 
drawn with prechilled syringes, transferred 
into three prechilled EDTA 10ml tubes and 
placed on ice packs. They were obtained at 
fasting early in the morning, and the serum 
was immediately separated by cold-
centrifugation (4°C) within several minutes of 
collection and stored at -20°C1, or -70°C or 
even at -130°C or colder until assay. 
Adiponectin is measured by: 
i. Enzyme-linked immunosorbent assay 
(ELISA): Arita et al. (1999), 
established the method for the 
determination of plasma 
adiponectin levels using ELISA 
technique, employing an 
adiponectin-specific antibody7. 
Plasma levels of adiponectin in 
human are substantially high, up to 
5 to 10 µg/mL on average, thus 
accounting for approximately 
0.01% of total plasma protein. 
Interestingly, plasma levels are 
negatively correlated with body 
mass index8,9. 
ii. Radioimmunoassay (RIA) method:  
Plasma adiponectin concentrations 
were measured by competitive 
radioimmunoassay (Linco 
Research Inc, St Charles, Mo) 
utilizing a highly purified antibody 
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raised against recombinant human 
adiponectin. Plasma adiponectin 
level in normal control people 
range between 11.6-22.9 (16.5 
mg/L)10,11.  
Receptors and mechanism of action of 
adiponectin 
As adiponectin is a protein hormone, it 
receptors is located in the cell membrane.  
It was reported that the cloning of adiponectin 
receptors in the skeletal muscle (AdipoR1) 
and liver (AdipoR2), which appear to 
comprise a novel cell-surface receptor family. 
They showed that AdipoR1 and AdipoR2 
serve as receptors for globular and full-length 
adiponectin and mediate increased AMP-
activated protein kinase (AMPK), peroxisome 
proliferator-activated receptor-α (PPAR 
α)ligand activities, and glucose uptake and 
fatty-acid oxidation by adiponectin12.  
The levels of AdipoR1 and AdipoR2 mRNA 
expression in the liver and skeletal muscle 
increased after fasting, and refeeding rapidly 
restored these to levels equal to the original 
fed state  
These observations suggested that insulin may 
negatively regulate AdipoR1/R2 mRNA 
levels in physiological and pathophysiological 
states such as fasting/refeeding, insulin 
deficiency, and hyperinsulinemia models, and 
it is correlated with adiponectin    
sensitivity13, 14.  
In skeletal muscle, both globular and full-
length adiponectin activate AMPK, thereby 
stimulating phosphorylation of ACC, fatty-
acid oxidation, and glucose uptake. 
Adiponectin activates PPAR α, thereby also 
stimulating fatty-acid oxidation and 
decreasing tissue TG content in muscle. In the 
liver, only full-length adiponectin activates 
AMPK, thereby reducing molecules involved 
in gluconeogenesis and increasing 
phosphorylation of acetyl coenzyme-A 
carboxylase (ACC) and fatty-acid oxidation. 
Adiponectin activates PPAR α, thereby 
stimulating fatty-acid oxidation and 
decreasing tissue TG content in the liver12, 15. 
Obesity decreased expression levels of 
AdipoR1/R2, thereby reducing adiponectin 
sensitivity, which finally leads to insulin 
resistance14, 15.  
 
In 2007 adiponectin receptors 1 and 2 mRNA 
expression in human breast cancer cells were 
demonstrated. It was suggested that 
adiponectin might modulate the growth of 
normal breast epithelial cells and breast 
cancer cells directly through AdipoR1 and 
AdipoR2 receptors, and that the association of 
low serum adiponectin levels with a high 
breast cancer risk might be explained, at least 
in part, by the direct effect of adiponectin on 
the breast epithelial cells16.  
 
 
Function of adiponectin 
Adiponectin is involved in a number of 
metabolic processes, such as glucose 
regulation and the metabolism of fat for 
energy production. 
Effects of Adiponectin on Insulin and 
Glucose Metabolism 
A. Insulin-sensitizing effects of 
adiponectin: Many mechanisms are 
involved as: 
i. Adiponectin decreases tissue TG 
content. Increased tissue TG 
content has been reported to 
interfere with insulin-stimulated 
phosphatidylinositol (PI) 3-kinase 
activation and subsequent glucose 
transporter 4 translocations and 
glucose uptake, leading to insulin 
resistance17. Thus, decreased tissue 
TG content in muscle may 
contribute to the improved insulin 
signal transduction.  Interestingly, 
in skeletal muscle, adiponectin 
increases expression of molecules 
involved in fatty-acid transport 
such as CD36, in combustion of 
fatty-acid such as acyl-coenzyme 
A oxidase, and in energy 
dissipation such as uncoupling 
protein 2. These changes led to 
decreased tissue TG content in 
skeletal muscle whether in 
experimental animals or in 
human18- 20.  
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ii. Direct insulin-sensitizing effect of 
adiponectin: an insulin-resistant 
lipoatrophic diabetic mouse model 
that displays both adiponectin and 
leptin deficiency was employed21. 
Replenishment of a physiological 
dose of recombinant adiponectin to 
the lipoatrophic diabetic mice 
significantly ameliorated insulin 
resistance19. Moreover, insulin 
resistance in lipoatrophic mice was 
completely reversed by the 
combination of physiological 
doses of adiponectin and leptin, 
but only partially by either 
adiponectin or leptin alone19. 
These data clearly indicate that 
adiponectin has a direct insulin-
sensitizing action. These data also 
suggest that leptin and adiponectin 
may be the two major insulin-
sensitizing hormones secreted 
from adipose tissue. 
iii. Decreased adiponectin and its 
receptors in obesity: It has been 
suggested that in obese people the 
decrease in adiponectin may play 
causal roles in the development of 
insulin resistance. AdipoR1/R2 are 
also decreased in obese people 
which will cause a decrease in 
adiponectin sensitivity, and finally 
leads to insulin resistance, and 
diabetes13. 
B. Effect of adiponectin on glucose 
metabolism: 
It has been reported that an acute increase in 
circulating adiponectin levels triggers a 
transient decrease in basal glucose levels by 
inhibiting both the expression of hepatic 
gluconeogenic enzymes and the rate of 
endogenous glucose production in both wild-
type mice and a type 2 diabetes mouse 
model22,23. 
 
Studies in severely obese Pima Indian 
subjects, (who have the highest known 
prevalence of obesity and type 2 diabetes in 
the world), have shown that subjects with 
high concentrations of adiponectin were 40% 
less likely to develop type 2 diabetes than 
those with low concentrations after 
adjustment for body mass index (BMI), 
indicating that adiponectin could be used as a 
predictor of future development of type 2 
diabetes in addition to the established risk 
parameters, such as BMI24, 25. 
 
Furthermore, Kubota et al provided the first 
direct evidence that adiponectin plays a 
protective role against insulin resistance by 
generating adiponectin-deficient mice. 
Heterozygous adiponectin-deficient (adipo 
(+/-)) mice showed mild insulin resistance, 
while homozygous adiponectin-deficient 
(adipo (-/-)) mice showed moderate insulin 
resistance with glucose intolerance despite 
body weight gain similar to that of wild-type 
mice26.  
 
It seems from the above data that adiponectin 
may provide a novel treatment modality for 
insulin resistance and type 2 diabetes. 
 
Effects of Adiponectin on Lipid 
Metabolism 
A. Effect of adiponectin on fatty-acid 
oxidation: 
Adiponectin participates in regulating 
energy balance by promoting lipid 
oxidation. It has been shown that FFA 
oxidation of adiponectin is due to 
activation of AMP-Kinase (AMPK) 
and peroxisome proliferator-activated 
receptor (PPARα) in the liver and 
skeletal muscle. In skeletal muscle, 
both globular and full-length 
adiponectin activate AMPK, thereby 
stimulating phosphorylation of acetyl-
CoA carboxylase (ACC), fatty-acid 
oxidation, and glucose uptake. While 
in the liver, only full-length 
adiponectin activates AMPK, thereby 
reducing molecules involved in 
gluconeogenesis and increasing 
phosphorylation of ACC and fatty-
acid oxidation. Adiponectin activates 
PPARα, thereby stimulating fatty-acid 
oxidation and decreasing tissue TG 
content in the liver20,27,28.  
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B. Effects of adiponectin on plasma 
lipids: 
Adiponectin decreases lipid synthesis 
and glucose production in the liver and 
causes decreases in glucose and free 
fatty acid concentrations in the blood. 
In addition, triglyceride production is 
decreased and fat oxidation and 
energy dissipation in the muscle are 
increased27,29,30. 
Adiponectin decreases body weight 
whether acting centrally on the brain 
by raising the metabolic rate while not 
affecting the appetite or acting 
peripherally by reducing lipid content 
in the body tissues whether in human 
or animal studies18-20. 
 
Adiponectin and the pathophysiology of 
obesity: 
It had been demonstrated that the expression 
of adipoQ mRNA is significantly reduced in 
the adipose tissues from obese mice and 
humans6. Then many studies have shown that 
the plasma adiponectin concentration is 
negatively correlated with body mass index 
(BMI) and accordingly, lower in obese than in 
lean subjects9,31-33. Furthermore, scientist 
extended these finding by demonstrating that 
plasma adiponectin concentrations are 
inversely related to percent body fat, a direct 
measure of adiposity, and that this is 
consistent across different ethnic groups. And 
these results thus confirm that adiponectin is 
the only adipose-specific protein known to 
date that, despite its exclusive production in 
white adipose tissue, is negatively regulated in 
obesity. This agrees with findings in rodents 
where the murine homologue of adiponectin, 
adipoQ, is also down-regulated in obesity and 
in obese humans, in which they reported a 
decreased of apM1 gene expression in 
subcutaneous and visceral adipose tissue6, 8, 34. 
These scientific data suggest that adiponectin 
may have a role in the pathogenesis of 
obesity.  
  
Anti-inflammatory Action of Adiponectin 
A. Functions of adiponectin in 
hematopoiesis and immune responses: 
Macrophages play a central role in 
immune responses by means of 
secretion of inflammatory cytokines 
(as TNF), phagocytic activity, and 
antigen presentation35.  Yokota et al 
showed that adiponectin  suppresses 
functions of mature macrophages, 
inhibiting their phagocytic activity and 
their production of TNF-alpha induced 
by bacterial lipopolysaccharides (LPS) 
which  suggest that adiponectin may 
have anti-inflammatory effects. But 
adiponectin did not suppress 
proliferation of erythroid or lymphoid 
cell lines except for one cell line36.  
Adiponectin seems to produce its 
effects on hematopoiesis and immune 
responses by means of mechanisms 
independent of PGE, because 
indomethacin, an inhibitor of PGE 
synthesis, could not abrogate 
adiponectin-induced suppression of 
colony formation and TNF-α 
expression36. 
The role of adiponectin in 
hematopoietic stem cell function was 
investigated and it was found that 
adiponectin is expressed by adipocytes 
in the bone marrow and that 
adiponectin receptors are expressed by 
hematopoietic stem cells. Adiponectin 
increases the proliferation of 
hematopoietic stem cells and retains 
them in a functionally immature state. 
Adiponectin signaling is required for 
optimal proliferation of hematopoietic 
stem cells in vitro and in long term 
hemopoietic reconstitution in vivo37. 
B. The effect of adiponectin on bone: It 
was demonstrated that adiponectin 
stimulates osteoblast growth but 
inhibits osteoclastogenesis, probably 
via an effect on stromal cells38. 
C. Anti-leukemic action: 
Adiponectin inhibits the growth of an 
acute myelomonocytic cell line, by 
inducing apoptosis36. 
The anti-inflammatory effects of adiponectin 
on blood vessels (antiatherogenic effect) have 
been discussed below.   
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Antiatherosclerotic actions of Adiponectin:  
Atherosclerotic diseases are the leading cause 
of death in developed countries and part of 
developing countries. Therefore, measures 
against atherosclerosis are the biggest medical 
subject in the 21st century39. 
Atherosclerotic cellular changes consist of 
basically the following three cellular 
phenomena: monocyte adhesion to 
endothelial cells by the expression of 
adhesion molecules, oxidized LDL uptake of 
macrophages through scavenger receptors, 
and proliferation of migrated smooth muscle 
cells by the action of platelet-derived growth 
factors or heparin-binding endothelial growth 
factor–like growth factor40.  
Adiponectin has potential inhibitory activities 
of these atherogenic cellular phenomena, i.e., 
it has a potential antiatherogenic activity as 
follows:  
i. Adiponectin was demonstrated to 
strongly inhibit the expression of 
adhesion molecules, including 
intracellular adhesion molecule-1, 
vascular cellular adhesion 
molecule-1, and E-selectin41.  
ii. Adiponectin was shown to inhibit the 
TNF-α–induced nuclear factor- κB 
activation through the inhibition of 
IκB phosphorylation, which might 
be a major molecular mechanism 
for the inhibition of monocyte 
adhesion to endothelial cells42,43.  
iii. Adiponectin inhibits lipid-laden foam 
cell formation (which is 
considered a key step in the 
pathogenesis of atherosclerosis); 
by reducing lipid accumulation 
(LDL) in human monocyte-derived 
macrophages through an inhibition 
of class A MSR (class A 
macrophages scavenger 
receptors)44.  
iv. Adiponectin inhibits the proliferation 
and migration of vascular smooth 
muscle cells. This inhibition was 
shown to be attributable to the 
binding competition to platelet-
derived growth factor-BB receptor 
of adiponectin and the inhibition of 
signal transduction through 
extracellular signal-related kinase 
(ERK)45,46.  
v. Anti-oxidant action: Hui et al 
described a novel vascular action 
of full-length adiponectin to 
stimulate production of NO (nitric 
oxide) from endothelial cells. 
Thus, adiponectin mimics vascular 
as well as metabolic actions of 
insulin41.  
The ability of adiponectin to 
stimulate production of NO in the 
vasculature may lead to 
vasodilation and increased blood 
flow that contributes to the effects 
of adiponectin to enhance glucose 
disposal. Moreover, the production 
of NO in the vasculature in 
response to adiponectin may also 
contribute to its anti-atherogenic 
properties. The fact that insulin 
and adiponectin regulate activation 
of eNOS (endothelial nitric-oxide 
synthase) by slightly different 
mechanisms suggests that 
therapies designed to increase 
adiponectin levels may be 
beneficial in the treatment of 
insulin resistance, diabetes, and its 
vascular complications47. 
vi. More over it was reported that HMW 
form of adiponectin has selective 
suppression of endothelial cell 
apoptosis via AMPK activation48. 
 
It is well known that in humans, many 
offensive factors are present, including 
oxidized LDL, inflammatory stimuli, and 
chemical substances that may induce vascular 
injuries which will end into atherosclerosis. 
Scientist have demonstrated experimentally 
that  adiponectin may go into the injured 
arteries and protect against the development 
of atherogenic vascular changes,  in which 
they showed that  neointimal thickening of 
damaged arteries is exacerbated in 
adiponectin-deficient  mice and is inhibited by 
exogenous adiponectin, due to its suppressive 
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effect on the inflammatory cytokines and 
adhesion molecules31,41,49. 
Furthermore, clinically, many scientists have 
reported that there is a low plasma 
adiponectin concentrations in patients with 
coronary artery disease, myocardial 
infarction10 and is also associated with some 
risk factors of cardiovascular disease, such as 
high blood pressure, obesity, and type II 
diabetes mellitus9,50-52. 
Therefore, adiponectin might be considered as 
firefighters who control the “fire” of the 
vascular walls while it is still small.  
In conclusion: 
 Adipose tissue is not considered anymore as 
a passive depot for storing excess energy in 
the form of triglycerides but as an active 
organ secreting several hormones or 
adipokines. 
  
Levels of adiponectin are inversely correlated 
with body mass index (BMI), and it seems to 
play a role in helping to stave off or 
ameliorate disorders such as obesity, diabetes, 
atherosclerosis cardiovascular disorders, and 
even malignancy. 
  
 Therefore, adiponectin levels hold great 
promise for use in clinical application serving 
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